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CORRESPONDENCE
Reply to ‘Comment on “The myth of pulmonary
metastasectomy’”
British Journal of Cancer https://doi.org/10.1038/s41416-020-
01062-6
We thank Zellweger and Gonzalez for their comments on our
article about pulmonary metastasectomy.1 We agree with much of
what they say about the need for multidisciplinary management
and the importance of ruling out other diagnoses such as primary
lung cancer, but we need to correct several misunderstandings.
The results of all 93 randomised patients in PulMiCC have now
been published in an updated report,2 which confirms the lack of
a significant survival difference (hazard ratio (HR) 0.93 (95%
confidence interval (CI): 0.56,1.56)) and median survivals of 3.5 and
3.8 years for intervention and control patients, respectively.
Although the numbers randomised were small, the trial has
sufficient power to make it highly improbable that the 5-year
survival rate in unoperated patients is <5%, as is so widely
believed.
Many reports and reviews of pulmonary metastasectomy cite
that low, <5%, estimate without any valid evidential support;
worse still, many quote the comparatively poor survival of patient
groups, which are not comparable because they do not have
same prognostic features as those selected for metastasectomy.
An example is the retrospective study by Kim et al.,3 in which the
comparator patients were significantly different in several
important prognostic factors. PulMiCC is the only randomised
controlled trial (RCT) with a truly comparable control population
and has clearly shown that survival without metastasectomy is
not as low as is so widely suggested. It also raises a serious
question as to whether or not the oft reported good survival of
those having pulmonary metastasectomy might be due to
selection alone.
In their landmark meta-analysis of prognostic factors following
pulmonary metastasectomy Gonzalez et al.4 included data from 25
reports. Of the 2600 for whom the data are available, 63% had a
solitary metastasis, a strongly favourable prognostic factor, and 5-
year survival was 41% when the data for the total 2925 patients (in
Table 1 of Gonzalez et al.) are aggregated. PulMiCC included 32
(34%) patients with solitary metastases. The overall estimated 4-
year survivals were 44% (operated) and 47% (controls)—survival
figures in both arms are comparable with those estimated from
Gonzalez et al.,4 despite PulMiCC having a lower proportion with
solitary metastasis.
The control patients were not ‘untreated’ but managed by their
local teams and 49% went on to have chemotherapy, as did 41%
in the metastasectomy arm. Consequently, the controls did not, as
implied, have any special treatment to account for their survival
compared with non-trial patients with metastatic colorectal
cancer.
Zellweger and Gonzalez do concede that ‘the survival benefit
for surgical patients is probably modest’ but are ‘…certain that
some patients will really benefit from curative surgical manage-
ment’ because ‘we observe daily that single or multiple pulmonary
metastasectomies may result in long-term survival or even cure’.
Unfortunately, anecdote and strong belief are not substitutes for
high-quality evidence and may, as has been seen often in the past,
lead to misguided or unnecessary treatment.5
They describe the difficulty of carrying out an RCT when only
one option is ‘potentially curative’ and this illustrates a very real
problem—namely, the lack of equipoise. If the clinicians
involved with explaining trial options to patients before trial
enrolment are certain that only one option offers a chance of
cure and therefore present the study to them in that way, then
recruitment will of course be difficult. A study of a sample of
those registered but not randomised in PulMiCC shows that if
the patients themselves chose which treatment to have, about
half opted not to have surgery, whereas if the surgical team
decided then almost all were operated on.6 This contrasts with
the assertion by Zellweger et al. that ‘many patients chose to
undergo surgery’.
We believe that the results of PulMiCC provide sufficient
evidence to generate doubt about the benefit of pulmonary
metastasectomy. Thus, a further large definitive RCT is both
ethical and essential. Unless the clinicians involved in such a trial
can adjust their mindsets, exhibit genuine equipoise around the
question and be more honest with patients about the lack of
clear evidence for the benefit of metastasectomy, then the
project is doomed to fail. Zellweger and Gonzalez think that
giving ‘desperate’ patients hope is a sufficient justification for
surgery. But giving patients hope with an uncertain promise of
cure seems inappropriate. Evidence suggests that however well
intentioned, giving patients misleading information may in fact
be harmful.7
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